Compare Summit Therapeutics Inc (SMMT) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs TJX Companies Inc — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while TJX Companies Inc trades at $126.94 (market cap $141.81B). The key difference: TJX Companies Inc is far larger — about 10.3× Summit Therapeutics Inc's market cap, and TJX Companies Inc pays a 1.49% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TJX | |
|---|---|---|
Market Cap | $13.79B | $141.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $168.41 |
52-Week Low | $12.43 | $126.10 |
Enterprise Value | $13.11B | $150.12B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
TJX Companies trades at $128.91, down 2.4% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company reported consistent earnings beats in recent quarters with Q2 2026 EPS of $1.22 exceeding the $1.19 estimate. Revenue growth remains robust, climbing from $48.5B in 2022 to $56.4B in 2025, while net margins improved to 8.63%. Recent news highlights TJX's expansion plans, raising its global store target to 7,500 locations.
The investment outlook remains positive given strong analyst support (84.6% buy ratings) and a $169 consensus price target representing 31% upside. However, near-term technical weakness and valuation concerns present risks. The stock's current P/E of 23.87 appears reasonable given the company's 62% ROE and consistent execution, though competitive pressures in off-price retail warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
